Analyst Reco. Singular Genomics Systems, Inc.

Equities

OMIC

US82933R1005

Market Closed - Nasdaq Other stock markets 01:30:00 01/05/2024 am IST			5-day change	1st Jan Change
0.401 ^USD	+0.88%		-3.23%	-12.85%

20/03	UBS Adjusts Singular Genomics Systems Price Target to $0.50 From $0.40, Maintains Neutral Rating	MT
18/03	Transcript : Singular Genomics Systems, Inc., Q4 2023 Earnings Call, Mar 18, 2024

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

UBS Adjusts Singular Genomics Systems Price Target to $0.50 From $0.40, Maintains Neutral Rating	20/03	MT
Goldman Sachs Trims Price Target on Singular Genomics Systems to $0.85 From $0.95, Maintains Neutral Rating	22/01	MT
UBS Adjusts Singular Genomics Systems Price Target to $0.40 From $0.90, Maintains Neutral Rating	12/23/12	MT
UBS Adjusts Singular Genomics Systems Price Target to $0.90 From $1, Maintains Neutral Rating	10/23/10	MT
Goldman Sachs Adjusts Price Target on Singular Genomics Systems to $1 From $1.15, Maintains Neutral Rating	10/23/10	MT
UBS Adjusts Price Target on Singular Genomics Systems to $1 From $1.25, Maintains Neutral Rating	10/23/10	MT
UBS Adjusts Singular Genomics Systems Price Target to $1.25 From $2.25, Maintains Neutral Rating	10/23/10	MT
UBS Adjusts Singular Genomics Systems Price Target to $2.25 From $2.50, Maintains Neutral Rating	06/23/06	MT
Goldman Sachs Adjusts Price Target on Singular Genomics Systems to $3 From $3.50, Maintains Neutral Rating	08/22/08	MT
UBS Adjusts Singular Genomics Systems Price Target to $2.50 From $4.50, Maintains Neutral Rating	08/22/08	MT
UBS Downgrades Singular Genomics Systems to Neutral From Buy, Adjusts Price Target to $4.50 From $10	17/22/17	MT
JPMorgan Downgrades Singular Genomics Systems to Neutral From Overweight	10/22/10	MT
BofA Securities Double Downgrades Singular Genomics Systems to Underperform From Buy; Price Target is $3	10/22/10	MT
Goldman Sachs Downgrades Singular Genomics Systems to Neutral From Buy; Price Target is $3.50	10/22/10	MT
Goldman Sachs Adjusts Singular Genomics Systems Price Target to $5 From $9.50, Maintains Buy Rating	14/22/14	MT
UBS Adjusts Singular Genomics Systems Price Target to $10 From $15, Maintains Buy Rating	12/22/12	MT
Goldman Sachs Adjusts Singular Genomics Systems Price Target to $9.50 From $11, Maintains Buy Rating	11/22/11	MT
Goldman Sachs Adjusts Singular Genomics Systems' Price Target to $11 from $17, Keeps Buy Rating	13/22/13	MT
UBS Adjusts Singular Genomics Systems Price Target to $15 From $25, Maintains Buy Rating	03/22/03	MT
BofA Securities Upgrades Singular Genomics Systems to Buy From Neutral, Sets $21 Price Target	07/22/07	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Singular Genomics Systems, Inc.

Equities

OMIC

US82933R1005

Analyst Reco.

Filters